Document is current
Any future updates will be listed below
-
Authors
Liu, Zhike
Li, Pei
Zeng, Xueyang
Yao, Xiaoying
Sun, Yexiang
Lin, Hongbo
Shen, Peng
Sun, Feng https://orcid.org/0000-0003-4334-6805
Zhan, Siyan
-
Funding
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
National key R&D Program of China (2021YFC2301601)
National Natural Science Foundation of China (82204175)
- License Information
-
More Information
Article History
Received: 5 July 2022
Accepted: 26 October 2022
First Online: 18 November 2022
Declarations
:
: The protocol for this study has been approved by the Peking University Institutional Review Board, which have accepted responsibility for supervising all aspects of the study (approval No: IRB00001052-22014). All subjects and/or their LARs who agree to participate in the study will sign informed consent.
: Not applicable.
: FS and PS, as the primary investigators from Peking University and Yinzhou CDC, will receive funding from GlaxoSmithKline Biologicals SA (GSK), which is the manufacturer of <i>cervarix</i> and will potentially benefit from the result of this study.
